Covance Is Now Labcorp Drug Development

We are one global company innovating for millions – together, continuing to bring you more advanced medical breakthroughs.

Learn More

Preclinical, Clinical Trials & Diagnostics

Immuno-oncology & Oncology

Contact Us

Your one source to achieve your next cancer breakthrough

More than half a million people with cancer will die this year; our mission is to be your one source to improve people's health and lives. 

From hundreds of preclinical tumor models and cell line assays to oncology clinical trials & post-market studies, we can help you get your next breakthrough cancer drug or precision medicine treatment to those who desperately need it.

Clinical Trials

In the last five years, our expertise, insights and market impact have been demonstrated in excess of 975 oncology studies (300 in immuno-oncology) across nearly 19,000 sites in 83 countries with more than 104,000 oncology patients. 

Embrace a personalized medicine approach that targets therapies to specific subsets of patients and begins in the preclinical phase of drug development. 
Technology is front and center of patient support programs today, but it isn’t a silver bullet. We need to balance technology with people and processes to achieve the right equilibrium of efficiency and risk.
Utilize biomarkers in clinical oncology development to provide key data for earlier decision making as well as patient and site selection

 

Co-develop a drug with an oncology companion diagnostics to help identify patients most likely to benefit from your next cancer breakthrough

Preclinical Immunotherapy

The industry has approached immuno-oncology from many angles, thus requiring identification, development and refinement of models capable of recapitulating optimal biological dynamics along with the associated and relevant endpoints.

Precision Medicine & Clinical Trials

Making gains in precision medicine for clinical trials requires novel methods to quickly test and target the right therapy to the right individual. In addition to dozens of late-stage immuno-oncology clinical trials, we have also supported more than 70% of all FDA-approved companion diagnostic products

Oncology Resources & Education

Oncology Events & Webinars

The Patient Journey in CAR T: Patient & Physician Perspectives
 

Let's start a conversation

Contact Us